--The below is a company-sponsored announcement--
Growing revenues put
Listed cannabis company
One of Creso's key goals is to bring pharmaceutical expertise and methodological rigor to the cannabis world as it strives for the highest quality in its products and this goal looks to be paying off.
The company completed 2020 backed by a number of important milestones:
- A growing number of Purchase Orders, which should soon equate to revenue.
- The appointment of former Canopy founder
Bruce Linton as an Advisor to CPH. - Regulatory Tailwinds, including the recent ruling by the EU's highest court, the CJEU, which ruled that cannabidiol isn't a narcotic drug and as such CBD can be freely sold in the
European Union (EU). This bodes well for sales of CPH products inEurope .
In the last two weeks,
This is of particular significance as a Democratic win is likely to catalyse constructive changes for federal cannabis reform: 2021 will see the first unified Democratic control of the
Throughout the election the Joe Biden campaign touted support for cannabis decriminalisation, with
Importantly, the development enhances the potential for Marijuana Opportunity Reinvestment and Expungement (MORE) Act to be passed in the
On
From its current position, Mernova could scale up operations to meet potential demand from the US market.
Creso is currently exploring several US market opportunities and is confident in its ability to enter this market swiftly. As a listed vehicle with access to capital, Creso is also an attractive partner for merger and acquisition opportunities.
Further sales boost revenues
As a company that prides itself on bringing the best of cannabis to better the lives of people and animals,
Delivery to Lupin follows the receipt of a second purchase order from Pharma Dynamics in
Pharma Dynamics is a subsidiary of leading pharmaceutical company,
Pharma Dynamics provides high-quality generic medicines at affordable prices and is well known for its investment in innovative wellness programs that "go beyond the pill" in helping patients manage their conditions and improve treatment outcomes.
Pharma Dynamics has a growing range of over-the-counter products include medications for cold and flu, allergy, and digestion, as well as immune booster wellness products.
Importantly, its products are consistently prescribed and recommended by leading doctors and pharmacists countrywide.
Commenting on the significance of receiving a second-order from Pharma Dynamics and the scope for further sales,
"cannaQIX® has been developed using Good Manufacturing Practice standards and is standardised and user-friendly.
"Strength and formulation allow for precise dosage control, and the lozenge form is more palatable than many other oils on the current market.
"We have no doubt that it will continue to be well received by consumers in
"We are very proud of having accomplished this delivery in spite of the current restrictions in place, mainly due to the COVID situation.
"We are looking forward to further growth throughout
The purchase order further contributes to CPH's cash balance.
As at
Since then, the company has received an additional
The company has also hinted at new opportunities and hopes to ratify these in the relative near-term, potentially providing further revenue growth share price momentum.
Earlier today the corporate announcement above was publicly released. FNArena is acting as a partner in distribution to broaden the reach. No journalists have been involved in the re-publication of this announcement.
Technical limitations
If you are reading this story through a third party distribution channel and you cannot see the illustration included, we apologise, but technical limitations are to blame.
FNArena is proud about its track record and past achievements: Ten Years On
All material published by
© 2021 Acquisdata Pty Ltd., source